Digest Network Come funziona
Network
/
Società
Sc
Non verificato

Scorpion Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
10/12/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478
Fonte
Scorpion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/10/2024
Mercato del lavoro
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Fonte
Scorpion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/09/2024
Industria
Scienza
Sanità
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024
Fonte
Scorpion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
19/08/2024
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
Fiere
Industria
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024
Fonte
Scorpion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/07/2024
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
Fonte
Scorpion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/07/2024
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
Fonte
Scorpion Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0